Sino Biopharmaceutical (01177) Report Interpretation

Overview

This earnings review examines Sino Biopharmaceutical’s 1H26 results, where weaker-than-expected revenue growth was more than offset by cost optimization and business-development income. Goldman Sachs remains Buy rated, highlighting the innovative-drug franchise, a differentiated next-generation pipeline and improved earnings expectations.

Core views

Sino Biopharmaceutical reported 1H26 revenue of Rmb19.4bn, up 10.6% year on year but below Goldman Sachs’ expectation for 14% growth. Excluding collaboration income from the Sanofi deal, underlying product sales rose about 5% YoY, which the report attributes to softer commercial execution. Generic-drug sales increased only 1% YoY as VBP renewals pressured pricing and prescribing became more cautious amid anti-corruption tightening. Innovative products, however, grew 29% YoY, supported by uptake of newly launched oncology medicines including zongertinib, a HER2 TKI; a CDK2/4/6 inhibitor; a KRAS G12C inhibitor; and PD-L1 products. Management nevertheless reiterated confidence in double-digit FY26 revenue growth including BD income and pointed to possible upside from further out-licensing deals. Profitability was materially stronger than the sales outcome implied. Net profit reached Rmb3.4bn, up 1.4% YoY and well above Goldman Sachs’ Rmb2.2bn estimate. Selling expenses fell 18% YoY, reducing the selling-expense ratio to 28% of product sales from 36.7% in 1H25. The report links this to fewer physician-engagement activities in the anti-corruption environment and company efficiency measures, including greater use of AI for commercial productivity and operating efficiency. R&D expense declined 3.4% YoY after management streamlined less competitive programmes through a pipeline review led by the new CMO. With operating leverage and BD income, adjusted core earnings excluding the SinoVac dividend rose 92% YoY; Goldman Sachs estimates that underlying core earnings still rose about 63% YoY even excluding BD income. The report also emphasizes the development pipeline as a source of longer-term differentiation and potential BD optionality. In chronic disease, HJY-22, a PCSK9/Lp(a) dual-target siRNA planned for an IND filing in 1Q27, is designed for potentially once-yearly dosing; preclinical lipid-lowering efficacy was comparable to a combination of two single-target siRNAs. In oncology, TQB6628, a PD-1/IL-2 fusion protein targeted for IND filing in 4Q26, uses affinity engineering intended to increase effector T-cell activation while reducing Treg engagement; the company said preclinical efficacy exceeded IBI363 and RG6279. TRD120, a CEA/CDH17 dual-target ADC targeted for IND filing in 1H27, may address tumour heterogeneity, while its exatecan payload could potentially address DXd-related resistance. Management reiterated a pace of about 20 IND filings annually, with Phase I data for Kylo-11 and preclinical data for a STAT6 PROTAC programme among upcoming catalysts. Following the results, Goldman Sachs raised 2026/27/28E earnings estimates by 21%/14%/9%, reflecting more aggressive expense reductions despite softer revenue growth. Its 12-month SOTP-based target price rises to HK$8.65 from HK$8.41. The target-price framework values the innovative pipeline at HK$96.3bn using DCF, generics at HK$59.9bn using a 10.0x exit P/E and 5-year CAGR of 5%, and anlotinib plus PD-(L)1 at HK$6.0bn using DCF. Goldman Sachs remains cautious about R&D resource allocation across group subsidiaries, but sees near-term drivers in new innovative-drug launches and potential additional BD deals supported by the company’s cash balance.

Analysis framework

Goldman Sachs first compares reported revenue and profit with its estimates and separates underlying product sales from collaboration income. It then explains earnings through selling and R&D cost movements, assesses pipeline milestones and BD potential, revises earnings forecasts, and derives a sum-of-the-parts target price from DCF valuations for selected innovative assets and an exit-P/E valuation for generics.

Methodology notes

• Valuation methodsSOTP (Sum-of-the-Parts) Valuation

  Sum-of-the-parts target-price valuation

  The report builds its HK$8.65 target price by separately valuing the innovative pipeline, generics, and anlotinib plus PD-(L)1 before combining those components.

• Valuation methodsDCF (Discounted Cash Flow)

  DCF valuation of innovative assets

  Goldman Sachs assigns DCF-based values of HK$96.3bn to the innovative pipeline and HK$6.0bn to anlotinib plus PD-(L)1.

• Valuation methodsP/E and PEG Valuation

  Exit P/E valuation for generics

  The generics business is valued at HK$59.9bn using a 10.0x exit P/E and a 5-year CAGR assumption of 5%.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Sino Biopharmaceutical (01177.HK)

  Primary covered company; Goldman Sachs views innovative-product growth, cost optimization and BD potential as drivers of resilient earnings.

  Strengths

  Innovative-product sales grew 29% YoY; selling costs declined sharply; the company has a broad next-generation pipeline and a strong cash balance.

  Weaknesses

  Underlying product-sales growth was about 5% YoY, below expectations, and generic sales grew only 1% YoY amid pricing pressure.

  Comparison

  The company said TQB6628 showed superior preclinical efficacy to IBI363 and RG6279.

  Risks

  Broader generic price cuts, pipeline approval delays, inefficient R&D allocation and slower-than-expected innovative-drug ramp-up.

Key data

• 1H26 revenueRmb19.4bn+10.6% YoY; below Goldman Sachs’ +14% expectation.
• Underlying product-sales growthc.5% YoYExcludes collaboration income from the Sanofi deal.
• Innovative-product sales growth+29% YoYSupported by new oncology-product uptake.
• Generic-drug sales growth+1% YoYAffected by VBP-renewal pricing pressure and a cautious prescribing environment.
• 1H26 net profitRmb3.4bn+1.4% YoY; versus Goldman Sachs estimate of Rmb2.2bn.
• Selling expenses-18% YoYSelling-expense ratio fell to 28% of product sales from 36.7% in 1H25.
• Adjusted core-earnings growth+92% YoYExcludes SinoVac dividend; Goldman Sachs estimates c.63% underlying growth excluding BD income.
• Earnings-estimate revisions+21%/+14%/+9%For 2026/27/28E, respectively.
• 12-month target priceHK$8.65Raised from HK$8.41.

Impact & implications

The report argues that cost discipline has made profitability more resilient than the softer topline suggests. It sees innovative-drug launches, pipeline milestones and possible further BD transactions as key supports for growth, while generic pricing pressure and R&D execution remain constraints.

Risks

• Broader price cuts across the generics portfolio could pressure sales and profitability.
• Regulatory approval delays for key pipeline products could postpone growth catalysts.
• Inappropriate R&D resource allocation could lower returns on R&D investment.
• Innovative drugs may ramp up more slowly than expected.

What to watch

• Whether FY26 revenue achieves management’s reiterated double-digit growth target, including BD income.
• Potential additional out-licensing or other BD deals.
• IND filings for TQB6628 in 4Q26, HJY-22 in 1Q27 and TRD120 in 1H27.
• Phase I data for Kylo-11 and preclinical data for the STAT6 PROTAC programme.
• The pace of uptake for newly launched innovative drugs and continued generic-drug pricing pressure.